NAD+

The Membrane Problem: Why NAD+ Doesn't Get In

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

NAD+ carries two negatively charged phosphates and does not cross plasma membranes. Extracellular NAD+ is also degraded by ectoenzymes including CD38. This is why the research field administers smaller precursors, and why effects following NAD+ administration most plausibly run through its breakdown products.

Key facts

Barrier
Two negative phosphate charges
Membrane crossing
Does not occur passively
Extracellular degradation
CD38 and other ectoenzymes
Likely fate
Cleaved to smaller precursors
Field's approach
Administer NR or NMN instead
NR size
255.25 Da, far smaller

The physical problem

A lipid bilayer is a hydrophobic barrier, and charged molecules do not cross it without a transporter. NAD+ carries two negative charges on its pyrophosphate bridge at physiological pH and is 663 Da besides. Both properties point the same way: it stays outside unless something actively carries it in.

What happens to it outside

CD38 is an ectoenzyme (an enzyme with its active site facing the outside of the cell) and it cleaves NAD+ as a substrate. So extracellular NAD+ is not simply sitting inert waiting to be taken up; it is being consumed. Covarrubias and colleagues reported in Nature Metabolism in 2020 that senescent cells drive tissue NAD+ decline specifically by increasing CD38 activity, which places this enzyme at the centre of the ageing story.

Research material referenced

NAD+ 500mg, third-party HPLC tested

Buy NAD+ · £49.99

Where the breakdown products go

Cleaving NAD+ yields smaller fragments including nicotinamide-containing species, and those are the molecules cells can take up and rebuild NAD+ from. This is the important inference: whatever effect follows administering NAD+ most plausibly proceeds through degradation to precursors, then uptake, then internal resynthesis, not through NAD+ arriving intact.

Which is why the trials use precursors

Nicotinamide riboside at 255.25 Da and nicotinamide mononucleotide at 334.22 Da are both far smaller and both have cellular uptake routes. Every substantial randomised human trial in this field, NADPARK, Orr's 2024 study, Yoshino's 2021 Science paper,used a precursor. That is not because NAD+ was unavailable to those researchers.

What follows practically

Administering NAD+ directly is a less direct route to raising cellular NAD+ than administering a precursor, not a more direct one, because the intact molecule cannot make the final step. It is a real pharmacological point and it is almost never made in commercial material about this compound.

Frequently asked questions

Can NAD+ enter cells?

Not passively. Two negative phosphate charges and 663 Da prevent it crossing a lipid bilayer.

What is CD38?

An ectoenzyme that cleaves NAD+ outside the cell. Covarrubias 2020 reported senescent cells drive tissue NAD+ decline by increasing its activity.

So how could administered NAD+ have any effect?

Most plausibly by being degraded to smaller precursors that cells can take up and rebuild NAD+ from internally.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More NAD+ articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.